U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.

Some 20 years after helping introduce the first once-daily single tablet HIV regimen, Gilead Sciences has crossed the regulatory finish line with a new oral treatment option in…